Haemonetics reported strong Q2 fiscal 2027 results with revenue of $357.8 million and raised its full-year revenue and organic growth outlook. The company highlighted continued adoption of its advanced plasma collection technologies and vascular closure products. Recent earnings calls provided detailed operational insights and positive market reception.

• Haemonetics reported second quarter fiscal 2027 revenue of $357.8 million [N5].
• The company raised its full-year revenue and organic growth outlook following Q2 results [N3][N6].
• Q2 earnings and revenues surpassed prior expectations, reflecting operational strength [N7].
• Recent earnings calls detailed ongoing adoption of NexSys PCS plasma collection systems and vascular closure technologies [N1][N2][N4].
• Haemonetics gained 149.3% in stock price over the past year, driven by strong operational performance and product innovation [N8].

Haemonetics benefits from growing demand for source plasma used in biopharmaceuticals and expanding minimally invasive hospital procedures requiring vascular closure and blood management technologies. Its continuous innovation and regulatory clearances for advanced plasma collection and vascular closure devices enhance its product offerings and customer value. The company's strong liquidity and recent revenue growth, including a raised full-year outlook, support operational flexibility and investment in growth initiatives. Strategic acquisitions, such as Vivasure Medical, may broaden its portfolio and market reach.

Challenges include regulatory and reimbursement risks in international markets where plasma collection regulations are less favorable than in the U.S., potentially limiting growth outside the U.S. The Blood Center segment faces more challenging market conditions with stable to slightly declining demand in mature markets. Competitive pressures in medical devices and the need for ongoing R&D investment may impact margins. Any delays or failures in obtaining regulatory approvals for new products could affect market penetration. Economic or healthcare spending downturns could reduce hospital procedure volumes and plasma collection demand.

Haemonetics' moat is supported by its specialized and FDA-cleared medical technologies in plasma collection and hospital vascular closure, which require significant regulatory approvals and clinical validation. Its integrated software solutions for plasma donor management and operational efficiency create switching costs for customers. The company's long-standing relationships and agreements with major U.S. plasma collectors, along with proprietary technologies like NexSys PCS with Persona PLUS, reinforce its competitive position. Additionally, its diversified product portfolio across plasma, blood center, and hospital segments provides resilience against market fluctuations in any single area.

• Regulatory Risks: The company operates in highly regulated markets requiring FDA and other approvals. Changes in regulations or delays in approvals could impact product launches and sales.
• Market Demand Variability: Demand for blood components and plasma can vary by region and procedure type, with mature markets showing stable or declining demand, affecting revenue growth.
• Competitive Pressure: Haemonetics faces competition from other medical device companies with potential impacts on pricing, market share, and innovation requirements.
• Operational Risks: Integration of acquisitions and execution of growth strategies carry risks. Supply chain disruptions or manufacturing issues could affect product availability.

• Haemonetics Corporation is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency through innovative solutions in hospital technologies, plasma collection, and blood center products [S1].
• The company operates in three principal segments: Plasma, Blood Center, and Hospital [S1].
• The Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions primarily for source plasma collection used in pharmaceutical manufacturing [S1].
• The Blood Center segment provides blood collection and processing devices and disposables for plasma, red cells, and platelets, serving blood centers that collect plasma for transfusions [S1].
• The Hospital segment includes Interventional Technologies (Vascular Closure, Sensor-Guided Technologies, Esophageal Protection) and Blood Management Technologies (Hemostasis Management, Cell Salvage, Transfusion Management) [S1].
• Haemonetics' Plasma business represented approximately 39.3% of total revenue in fiscal 2026 [S1].
• The Blood Center business represented about 16.6% of total revenue in fiscal 2026 [S1].
• The company has developed and received FDA clearances for advanced plasma collection technologies such as NexSys PCS with Persona PLUS technology, enhancing plasma yield per donation [S1].
• Haemonetics has agreements with all U.S. plasma customers to adopt NexSys PCS and its donor management software, with completed conversions to advanced technologies by fiscal 2026 end [S1].
• The Hospital segment's Vascular Closure products, including VASCADE and PerQseal Elite, address vascular access site closure needs in catheter-based procedures and have received FDA approvals and CE Mark in Europe [S1].
• Haemonetics reported second quarter fiscal 2027 revenue of $357.8 million and raised its full-year revenue and organic growth outlook following Q2 results [N3][N5][N6].
• The company reported net income of $46.3 million and basic EPS of $1.02 for the quarter ended September 26, 2026 [S2].
• Liquidity ratios as of September 26, 2026, include a current ratio of 2.84 and a cash ratio of 0.87, with cash and equivalents totaling approximately $260.7 million [S2].
• Recent news highlights include Q2 2027 earnings call details, revenue growth of 9% in Q2, and positive market reactions to earnings and revenue performance [N1][N2][N3][N6][N7].
• Haemonetics acquired Vivasure Medical Limited in early 2026, expanding its portfolio [N/A in provided citations but mentioned in news].
• The company’s products serve critical medical needs such as plasma collection for pharmaceuticals, blood component collection for transfusions, and hospital technologies that improve patient care and reduce costs [S1].